In the News

Le Dauphine Libere
National Institute for Health Research
Lokalzeit aus Bonn (March 26, 2015)
9 News (March 9, 2015)
WDRB (March 1, 2015)
The Courier-Journal (Feb 25, 2015)
Clinica (Feb 2, 2015)
U of L Today (Jan 28, 2015)

Press Releases

REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for...

Read more

SAN DIEGO and REDWOOD CITY, Calif. – May 22, 2018 – Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD)....

Read more

Zephyr EBVs are the Only Minimally-Invasive, Removable Devices for Emphysema with Validated Diagnostic Tool to Select Patients Likely to Benefit from Treatment

Read more

REDWOOD CITY, Calif. – December 20, 2017 – Pulmonx® Corp. today announced that the UK's National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD), and now...

Read more

Washington DC and Redwood City, Calif. – May 23, 2017 – Pulmonx, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without...

Read more
CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.
US / new visitor